Canadian Pharmacists Association
Canadian Pharmacists Association
Login /Register   Français
Menu Item
CPhA Logo
Search pharmacists.ca

COVID-19 Resources Archive

As the environment and information surrounding the pandemic has evolved, we have archived a number of our resources and tools developed over the past year.

Practice Resources

  • Protecting the Front Line: COVID-19 Day-to-Day Questions: CPhA has created an FAQs resource to help pharmacists manage day-to-day questions about COVID-19 in their pharmacies. This information is meant to support policy, practice and clinical guidelines being developed across the country, and will answer key questions pharmacists may have when supporting their patients during the pandemic. (Updated March 25, 2021)
  • Personal Protective Equipment (PPE): Suggested Best Practices for Pharmacies During the COVID-19 Pandemic: CPhA has updated its suggested best practices on the use of PPE by pharmacy staff. Changes include considerations for use of non-medical masks/cloth masks/cloth face coverings as a source control measure, additional clarity on applying point-of-care risk assessments to determine when and what PPE is required and the application of these PPE best practices for immunizations. (Updated May 29, 2020)
  • Staffing and Business Considerations if a Pharmacy Team Member Becomes Ill: CPhA and the Neighbourhood Pharmacy Association of Canada have developed a list of key considerations for pharmacy managers/owners to help them prepare for next steps if a pharmacy staff member is exposed to or infected with COVID-19. This document will help pharmacies prepare for staff reductions or store closures and offers guidance on staff reductions, self-assessment and connecting with local public health units. (April 16, 2020)

Drug Therapy Info

  • Treatment of COVID-19 with chloroquine or hydroxychloroquine: There is insufficient evidence that chloroquine or hydroxychloroquine will prevent or treat COVID-19. Use of chloroquine or hydroxychloroquine for COVID-19 should be restricted to use in clinical trials until more data are available. (Updated July 10, 2020)
  • Antiretroviral combinations: The limited evidence available regarding the safety and effectiveness of these medications in the treatment of COVID-19 illness shows no benefit in severely ill patients. (Updated May 26, 2020)
  • H2-receptor antagonist (H2RA) Shortages:CPhA and medSask developed this document to assist health-care providers in managing patient care in the event of a shortage of  H2-receptor antagonist (H2RA). (May 25, 2020)
  • Dipyridamole/ASA Shortage: CPhA and medSask developed this document to assist health care providers in managing patient care in the event of a shortage of dipyridamole/ASA. (April 30, 2020)
  • Therapeutic alternatives to amoxicillin for common pediatric conditions: CPhA and medSask developed this document to assist health care providers in managing patient care in the event of a shortage of amoxicillin suspension. (April 29, 2020)
  • Inhaled Salbutamol Shortage: CPhA and medSask developed this document to assist health care providers in managing patient care during the current salbutamol shortage. (April 16, 2020)
  • Fluticasone Propionate Pressurized Metered Dose Inhaler Shortage: CPhA and medSask developed this document to assist health care providers in managing patient care during the current fluticasone shortage. (April 2, 2020)
  • Use of NSAIDs in patients with COVID-19: what is the evidence? There is insufficient evidence that NSAIDs negatively impact morbidity or mortality of COVID-19 and Health Canada continues to recommend both ibuprofen and acetaminophen for treatment of fever due to COVID-19. (March 17, 2020)

Awareness Resources

Explainer videos:

  • A CPhA Explainer: Drug Myths and COVID-19
  • A CPhA Explainer: Maintaining a stable drug supply (YouTube)

Posters: